ArticleObesity surgery2026
Secondary Hyperparathyroidism in Post-Bariatric Population: A Descriptive Analysis.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary hyperparathyroidism (SHPT) is a known metabolic disturbance following bariatric surgery (BS), often driven by alterations in calcium, phosphorus, and vitamin D metabolism. Despite its recognition, the prevalence of SHPT in the Middle East and Northern Africa region remain unclear. This study aims to describe the prevalence of SHPT in a cohort of post-bariatric surgery patients of the region.
methodsWe conducted a retrospective analysis of patients who underwent primary laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) at our institution between January 2022 and December 2024. We focused on those with available postoperative parathyroid hormone measurements one year after the index procedure and defined secondary hyperparathyroidism as a PTH level greater than 6.9 pmol/L. Biochemical parameters, including vitamin D, phosphorus, calcium, albumin, creatinine, and alkaline phosphatase were collected and analyzed.
resultsAmong the 229 patients included in the study, 90 (39.3%) exhibited elevated postoperative parathyroid hormone (PTH) levels (>6.9 pmol/L), indicating a substantial prevalence of secondary hyperparathyroidism (SHPT). The mean age of the cohort was 35.42 ± 10.86 years, and the mean preoperative BMI was 41.83 ± 6.52 kg/m². The average time from surgery to PTH measurement was 483.46 ± 254.38 days. Patients with SHPT had slightly lower mean vitamin D levels (20.4 ± 11.8 ng/mL) compared to those without SHPT (22.1 ± 11.8 ng/mL), though this difference was not statistically significant. Notably, alkaline phosphatase levels were significantly higher in the SHPT group (80.6± 28.7 U/L vs. 70.2 ± 35.8 U/L; p = 0.0158).
conclusionSecondary hyperparathyroidism was found in 40% of patients after bariatric surgery, which is a significant prevalence warranting attention in clinical practice. Although the root causes remain unclear, this data emphasizes the need for further research to explore the mechanisms driving SHPT post-surgery. Persistent vitamin D deficiency and elevated alkaline phosphatase levels highlight the importance of routine biochemical monitoring and timely interventions. Early identification of at-risk patients and tailored supplementation strategies are essential to reduce the risk of long-term bone metabolism complications.
Indexed as
Identifiers
41832392What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.